Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis
B Melosky, K Kambartel, M Haentschel… - Molecular Diagnosis & …, 2022 - Springer
Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …
[HTML][HTML] The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
YL Zhang, JQ Yuan, KF Wang, XH Fu, XR Han… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Objectives Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …
[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Y Kobayashi, T Mitsudomi - Cancer science, 2016 - Wiley Online Library
Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …
Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer
M Chen, Y Xu, J Zhao, W Zhong, L Zhang, Y Bi… - …, 2019 - thelancet.com
Abstract Background Tyrosine kinase inhibitors (TKIs) are clinically effective in non-small
cell lung cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) …
cell lung cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) …
[HTML][HTML] Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on …
YL Wu, WZ Zhong, LY Li, XT Zhang, L Zhang… - Journal of Thoracic …, 2007 - Elsevier
Background Convincing data on epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10%
of EGFR mutations, harboring heterogeneous molecular alterations within exons 18–21 with …
of EGFR mutations, harboring heterogeneous molecular alterations within exons 18–21 with …
Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer
Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
N Girard, CS Sima, DM Jackman… - European …, 2012 - Eur Respiratory Soc
Epidermal growth factor receptor (EGFR) tumour genotyping is crucial to guide treatment
decisions regarding the use of EGFR tyrosine kinase inhibitors in nonsmall cell lung cancer …
decisions regarding the use of EGFR tyrosine kinase inhibitors in nonsmall cell lung cancer …
Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology–mainland China subset analysis …
Y Shi, J Li, S Zhang, M Wang, S Yang, N Li, G Wu… - PloS one, 2015 - journals.plos.org
Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to
EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation …
EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation …
相关搜索
- growth factor receptor mutations
- worldwide prevalence receptor mutations
- lung cancer receptor mutations
- growth factor worldwide prevalence
- lung cancer growth factor
- worldwide prevalence meta analysis
- growth factor meta analysis
- asian patients egfr mutations
- meta analysis receptor mutations
- lung cancer asian patients
- treatment strategy receptor mutations
- lung cancer treatment strategy
- growth factor treatment strategy
- adenocarcinoma histology egfr mutations
- molecular epidemiology egfr mutations
- lung adenocarcinoma presence of egfr